Eli Lilly said it expects to increase its diabetes sales force by 40% in 2007.The move comes as Lilly plans launch five new insulin pen delivery products and bolster efforts behind its recently launched diabetes treatment Byetta, Lilly president John Lechleiter told investors last Thursday. Byetta’s new-prescription volume increased 30% over the last month, Lilly said. The drug also recently won approval to be marketed in Europe.